Stem Cell Factor and Chronic Myeloid Leukemia CD34+ Cells

References

• Shtivelman E, Lifshitz B, Gale R P, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 1985; 315: 550–554
   PubMed Web of Science ®Google Scholar
• Bedi A, Zehnbauer R A, Barber J P, Sharkis S J, Jones R J. Inhibition of apoptosis by BCR-ABL in chronic myelogenous leukemia. Blood 1994; 83: 2038–2044
   PubMed Web of Science ®Google Scholar
• Amos T AS, Lewis J L, Grand F H, Gooding R P, Goldman J M, Gordon M Y. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. British Journal of Haematology 1995; 91: 387–393
   PubMed Web of Science ®Google Scholar
• Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky W E. Primary proliferating immature myeloid cells from CML Patients are not resistant to induction apoptosis by DNA damage and growth factor withdrawal. British Journal of Haematology 1996; 95: 501–507
   PubMed Web of Science ®Google Scholar
• Gordon M Y, Dazzi F, Marley S B, Lewis J L, Nguyen D, Grand F H, Davidson R J, Goldman J M. Cell biology of CML cells. Leukemia 1999; S65–S71, Suppl. 1
   Google Scholar
• Raskind W H, Fialkow P J. The use of cell markers in the study of human hematopoietic neoplasia. Advances in Cancer Research 1987; 49: 127–67
   PubMed Web of Science ®Google Scholar
• Strife A, Lambek C, Wisniewski D, Wachter M, Gulati S C, Clarkson B D. Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Research 1988; 48: 1035–1041
   PubMed Web of Science ®Google Scholar
• Stryckmans P A, Debusscher L, Collard E. Cell kinetics in chronic granulocytic leukaemia (CGL). Clinical Hae-matology 1977; 6: 21–40
   PubMed Web of Science ®Google Scholar
• Pedersen B. Kinetics and cell function. Chronic Granulocytic Leukemia, M. T. Shaw. Praeger Scientific Publishers, Eastbourne, New York 1982; 93–135
   Google Scholar
• Thiele J, Zirbes T K, Lorenzen J, Kvasnicka H M, Dresbach S, Manich B, Leder L D, Niederle N, Diehl V, Fischer R. Apoptosis and proliferation (PCNA labelling) in CML: a comparative immunohistological study of bone marrow biopsies following interferon and busulphan therapy. Journal of Pathology 1997; 181: 316–322
   PubMed Web of Science ®Google Scholar
• Eaves C J, Eaves A C. Stem Cell Kinetics. In Bailliere's Clinical Haematology 1997; 10: 233–257
   PubMed Web of Science ®Google Scholar
• Veena P, Cornetta K, Davidson A, Aguero B, McMahal J, Traycoff C, Srour E. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells. Bone Marrow Transplantation 1997; 19: 1213–1221
   PubMed Web of Science ®Google Scholar
• Traycoff C M, Halstead B, Rice S, McMahel J, Srour E F, Cornetta K. Chronic myelogenous leukaemia CD34+ cells exit G0/G1 phases of cell cycle more rapidly than normal marrow CD34+ cells. British Journal of Haematology 1998; 102: 759–767
   PubMed Web of Science ®Google Scholar
• Gordon M Y, Dowding C R, Riley G P, Goldman J M, Greaves M F. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987; 328: 342–344
   PubMed Web of Science ®Google Scholar
• Verfaillie C M, McCarthy J B, McGlave P B. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. Journal of Clinical Investigation 1992; 90: 1232–1241
   PubMed Web of Science ®Google Scholar
• Bhatia R, Munthe H A, Verfaillie C M. Role of abnormal integrin-cytoskeletal interactions in impaired beta 1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Experimental Hematology 1999; 27: 1384–1396
   PubMed Web of Science ®Google Scholar
• Kovach N L, Lin N, Yednock T, Harlan J M, Broudy V C. Stem cell factor modulates avidity of a4p51 and cc5pl integrins expressed on hematopoietic cell lines. Blood 1995; 85: 159–167
   PubMed Web of Science ®Google Scholar
• Levésque J-P, Leavesley D I, Niutta S, Vadas M, Simmons P J. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. Journal of Experimental Medicine 1995; 181: 1805–1815
   PubMed Web of Science ®Google Scholar
• Cashman J D, Eaves C J, Sards A H, Eaves A C. MCP-1, not MIP-1α, is the endogenous chemokine that cooperates with TGF-β to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 1998; 92: 2338–2344
   PubMed Web of Science ®Google Scholar
• Upadhyaya G, Guba S, Sih S, Feinberg A, Talpaz M, Kantarjian H, Deisseroth A, Emerson S. Interferon-alpha restores the deficient expression of the cyto-adhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. Journal of Clinical Investigation 1991; 88: 2131–2136
   PubMed Web of Science ®Google Scholar
• Ghaffari S, Dougherty G J, Eaves A C, Eaves C J. Diverse effects of anti-CD44 antibodies on the stromal cell-mediated support of normal but not leukaemic (CML) haematopoiesis in vitro. British Journal of Haematology 1997; 97: 22–28
   PubMed Web of Science ®Google Scholar
• Moore S, Haylock D N, Lévesque J P, McDiarmid L A, Samels L M, To L B, Simmons P J, Hughes T P. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of CML CD34+ cells. Blood 1998; 92: 2461–2470
   PubMed Web of Science ®Google Scholar
• Fogli M, Amabile M, Martinelli G, Fortuna A, Rondelli D, Ratta M, Curti A, Tura S, Lemoli R M. Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. British Journal of Haema-tology 1998; 101: 119–129
   PubMed Web of Science ®Google Scholar
• Argawal R, Doren S, Hicks B, Dunbar C E. Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor deficient stroma favors benign progenitors. Blood 1995; 85: 1306–1312
   PubMed Web of Science ®Google Scholar
• Hallek M, Danhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb H J, Druker B, Griffin J D, Emmerich B, Ullrich A. Interaction of the receptor tyrosine kinase pl45c-kit with the p210bcr/abl kinase in myeloid cells. British. Journal of Haematology 1996; 94: 5–16
   PubMed Web of Science ®Google Scholar
• Yarden Y, Kuang W J, Yang-Feng T, Coussens L, Munemitsu S, Dull T J, Chen E, Schlessinger J, Francke U, Ullrich A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO Journal 1987; 6: 3341–3351
   PubMed Web of Science ®Google Scholar
• Qui F, Ray P, Brown K, Barker P E, Jhanwar S, Ruddle F H, Besmer P. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family- oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO Journal 1988; 7: 1003–1011
   PubMed Web of Science ®Google Scholar
• Birg F, Courcoul M, Rosnet O, Bardin F, Pebusque M J, Marchetto S, Tabilio A, Mannoni P, Birnbaum D. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992; 80: 2584–2593
   PubMed Web of Science ®Google Scholar
• Wang C, Curtis J E, Geissler E N, McCulloch E A, Minden M D. The expression of the proto-oncogene c-kit in the blast cells of acute myeloblastic leukemia. Leukemia 1989; 3: 699–702
   PubMed Web of Science ®Google Scholar
• Mayrhofer G, Gadd S J, Spargo L DJ, Ashman L K. Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues. Immunology and Cell Biology 1987; 65: 241–250
   PubMed Web of Science ®Google Scholar
• Majumder S, Brown K, Qui F H, Besmer P. C-kit protein, a transmembrane kinase: Identification in tissues and characterization. Molecular and Cellular Biology 1988; 8: 4896–4903
   PubMed Web of Science ®Google Scholar
• Nocka K, Majumder S, Chabot B, Ray M, Cervone A, Bernstein A, Besmer P. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - evidence for an impaired c-kit kinase in mutant mice. Genes & Development 1994; 3: 816–826
   Web of Science ®Google Scholar
• Matos M E, Schnier G S, Beecher M S, Ashman L K, William D E, Caligiuri M A. Expression of a functional c-kit receptor on a subset of natural killer cells. Journal of Experimental Medicine 1993; 178: 1079–1084
   PubMed Web of Science ®Google Scholar
• Grabarek J, Groopman J E, Lyles Y R, Jiang S, Bennett L, Zsebo K, Avraham H. Human kit ligand (stem cell factor) modulates platelet activation in vitro. Journal of Biological Chemistry 1994; 269: 21718–21724
   PubMed Web of Science ®Google Scholar
• Broudy V C, Kovach N L, Bennett L G, Lin N, Jacobsen F W, Kidd P G. Human umbilical vein endothelial cells display high affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 1994; 83: 2145–2152
   PubMed Web of Science ®Google Scholar
• Torihashi S, Ward S M, Nishikawa S I, Nishi K, Kobayashi S, Sanders K M. C-kit dependent development if interstitial cells and electrical activity in the murine gastrointestinal tract. Cell and Tissue Research 1995; 280: 97–111
   PubMed Web of Science ®Google Scholar
• Huizinga J D, Thuneberg L, Klueppel M, Malysz J, Mikkelsen H B, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 347–349
   PubMed Web of Science ®Google Scholar
• Natali P G, Nicotra M R, Sures I, Santoro E, Bigotti A, Ullrich A. Expression of the c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Research 1992; 52: 6139–6143
   PubMed Web of Science ®Google Scholar
• Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cado C. Expression of c-kit and kit-ligand proteins in normal human tissues. Journal of Histochemistry and Cytochemistry 1994; 42: 1417–1425
   PubMed Web of Science ®Google Scholar
• Blechman J M, Lev S, Brizzi MLeitner F. O., Pegoraro L, Givol D, Yarden Y. Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. Journal of Biological Chemistry 1993; 268: 4399–4406
   PubMed Web of Science ®Google Scholar
• Blechman J M, Lev S, Barg J, Eisenstein M, Vaks B, Vogel Z, Givol D, Yarden Y. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 1995; 80: 103–113
   PubMed Web of Science ®Google Scholar
• Van der Geer P, Hunter T, Lindberg R A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annual Review of Cell Biology 1994; 10: 251–337
   PubMedGoogle Scholar
• Wisniewski D, Strife A, Berman E, Clarkson B. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phophotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia. Leukemia 1996; 10: 229–237
   PubMed Web of Science ®Google Scholar
• Clarkson B D, Strife A, Wisniewski D, Lambek C, Carpino N. New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia 1997; 11: 1404–1428
   PubMed Web of Science ®Google Scholar
• Heinrich M C, Dooley D C, Freed A C, Band L, Hoatlin M E, Keeble W W, Peters S T, Silvey K V, Ey F S, Kabat D. Constitutive expression of steel factor gene by human stromal cells. Blood 1993; 82: 771–783
   PubMed Web of Science ®Google Scholar
• Caruana G, Ashman L K, Fujita J, Gonda T J. Responses of the murine myeloid cell line FDC-P1 to soluble and membrane forms of steel factor (SLF). Experimental Hematology 1993; 21: 761–768
   PubMed Web of Science ®Google Scholar
• Miyazawa K, Williams D A, Gotoh A, Nishimaki J, Broxmeyer H E, Toyama K. Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene encoded protein than its soluble form. Blood 1995; 85: 641–649
   PubMed Web of Science ®Google Scholar
• Fujita J, Onoue H, Ebi Y, Nakayama H, Kanakura Y. In vitro duplication and in vivo cure of mast cell deficiency of Sl/Sld mutant mice by cloned 3T3 fibroblasts. Proceedings of the National Academy of Sciences (USA) 1989; 86: 2888–2891
   PubMed Web of Science ®Google Scholar
• Toksoz D, Zsebo K M, Smith K A, Hu S, Brankow D, Suggs S V, Martin F H, Williams D A. Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proceedings of the National Academy of Sciences (USA) 1992; 89: 7350–7354
   PubMed Web of Science ®Google Scholar
• Kapur R, Majumdar M, Xiao X G, McAdrews-Hill M, Schindler K, Williams D A. Signalling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: Genetic evidence for a differential role in erythropoiesis. Blood 1998; 91: 879–889
   PubMed Web of Science ®Google Scholar
• Gore S D, Amin S, Weng L J, Civin C I. Steel factor supports the cycling of isolated human CD34+ cells in the absence of other growth factors. Experimental Hematology 1995; 23: 413–421
   PubMed Web of Science ®Google Scholar
• Issaad C, Vainchenker W. Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor. Blood 1994; 84: 3447–3456
   PubMed Web of Science ®Google Scholar
• Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield J H, Ashman L K, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand independent activation of c-kit product. Journal of Clinical Investigation 1993; 92: 1736–1744
   PubMed Web of Science ®Google Scholar
• Longley B J, Tyrrell L, Lu S Z, Ma Y S, Langley K, Ding T G, Duffy T, Jacobs P, Tang L H, Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nature Genetics 1996; 12: 312–314
   PubMed Web of Science ®Google Scholar
• Nagata H, Worobec A S, Oh C K, Chowdhury B A, Tanan-Baum S, Suzuki Y, Metcalf D D. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Procedings of the National Academy of Science 1995; 92: 10560–10564
   PubMed Web of Science ®Google Scholar
• Pignon J M, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W, Vernant J P, Tulliez M. A new c-kit mutation in a case of aggressive mast cell disease. British Journal of Haematology 1997; 96: 374–376
   PubMed Web of Science ®Google Scholar
• Kimura A, Nakata Y, Katoh O, Hyodo H. C-kit point mutation in patients with myeloproliferative disorders. Leukemia and Lymphoma 1997; 25: 281–287
   PubMed Web of Science ®Google Scholar
• Beghini A, Larizza L, Cairoli R, Morra E. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells Mol. Dis. 1998; 24: 262–270
   PubMed Web of Science ®Google Scholar
• Ashman L K, Ferrrao P, Cole S R, Camareri A C. Effects of mutant c-kit in early myeloid cells. Leukemia and Lymphoma 1999; 34: 451–461
   PubMed Web of Science ®Google Scholar
• Cole S R, Aylett G W, Casey G, Harvey N L, Cambareri A C, Ashman L K. Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukemia. Leukemia 1996; 10: 288–296
   PubMed Web of Science ®Google Scholar
• Jiang X, Eaves A, Eaves C. IL-3 and G-CSF gene expression in primitive Ph+ CD34+ cells from patients with chronic myeloid leukemia (CML). Blood 1997; 90: 392a, (abstr)
   Google Scholar
• Zhang X, Ren R. Bcr-Abl efficiently induces myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukaemia. Blood 1998; 92: 3829–3840
   PubMed Web of Science ®Google Scholar
• Dunbar C E, Browder T M, Abrams J S, Nienhuis A W. COOH-Terminal-Modified Interleukin-3 is retained intracell-ullarly and stimulates autocrine growth. Science 1989; 245: 1493–1496
   PubMed Web of Science ®Google Scholar
• Mahon F X, Pigoennier-Lagarde V, Chahine H, Barbot C, Jazwiec B, Ripoche J, Reiffers J. Ex vivo cytokine expansion of peripheral blood 5-fluorouracil-treated CD34-positive chronic myeloid leukaemia cells increases the selection of Ph-negative cells. British Journal of Haematology 1997; 98: 467–473
   PubMed Web of Science ®Google Scholar
• Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukaemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056–2064
   PubMed Web of Science ®Google Scholar
• Sawyers C L, Druker B. Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer Journal from Scientific American 1999; 5: 63–69
   PubMed Web of Science ®Google Scholar